A $623 million company just raised full-year guidance for the second straight quarter, lifting LINZESS U.S. net sales to $1.20 billion to $1.25 billion. Operating cash flow nearly tripled to $130.8 million.
Latest Activity
IRWD Coverage
Billionaire Healthcare Investor Alex Denner’s Hedge Fund Has 75% of Its Assets in These 3 Stocks
If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. Denner is the CEO and CIO of Sarissa Capital…
Tuesday’s Top Analyst Upgrades and Downgrades: Broadcom, Deere, FedEx, Lululemon, LyondellBasell, Nvidia, Starbucks and More
Tuesday's top analyst upgrades and downgrades included Broadcom, Ciena, Deere, FedEx, IMAX, Ironwood Pharmaceuticals, Lululemon Athletica, LyondellBasell Industries, Nvidia and Starbucks.
Top Analyst Upgrades and Downgrades: Allscripts, AmeriGas, CVS, IMAX, Kraft Heinz, Marathon Oil, Microsoft, Pfizer and Many More
The top analyst upgrades, downgrades and initiations seen for Monday included Allscripts Healthcare Solutions, AmeriGas Partners, CVS Health, IMAX, Kraft Heinz, Marathon Oil, Microsoft and Pfizer.
Top Analyst Upgrades and Downgrades: AIG, Freeport-McMoRan, Frontier Communications, Noble Energy, Occidental, Spark Therapeutics, Target and More
The top analyst upgrades, downgrades and initiations seen on Wednesday included AIG, Freeport-McMoRan, Frontier Communications, Noble Energy, Occidental Petroleum, Spark Therapeutics and Target.
Meet Merrill Lynch’s Top Biotech Picks for 2018
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming…
Top Analyst Upgrades and Downgrades: AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline, Square and Many More
The top analyst upgrades, downgrades and other research calls from Monday include AECOM, Ciena, Evoqua Water Tech, Funko, GlaxoSmithKline and Square.
Ironwood Pharma Muted Despite FDA Approval
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares remained relatively muted on Monday after the firm announced a key U.S. Food and Drug Administration (FDA) approval for its gout treatment duzallo. The firm expects…
JPMorgan’s Favorite Biotechs to Buy With Massive Upside Potential
After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, biotech stocks are showing some signs of life.
Top Analyst Upgrades and Downgrades: Anadarko, Apple, Charter Communications, FireEye, First Solar, Frontier Communications and More
The top analyst upgrades, downgrades and other research calls from Wednesday include Anadarko, Apple, Charter Communications, FireEye, First Solar and Frontier Communications.
Top Analysts Upgrades and Downgrades: Alphabet, Apple, Duke Energy, Kellogg, NVIDIA, Wells Fargo and More
Wednesday's top analyst upgrades, downgrades and initiations include Alphabet, Apple, Duke Energy, Kellogg, NVIDIA and Wells Fargo.
Top Analyst Upgrades and Downgrades: AK Steel, Intel, Symantec, Tesla, US Steel, Valeant and More
The top analyst upgrades, downgrades and initiations seen on Monday, March 21, include AK Steel, Intel, Symantec, Tesla, US Steel and Valeant Pharmaceuticals.
Top Analyst Upgrades and Downgrades: Google, GoPro, Infinity Pharma, 3D Systems, LifeLock and More
These are the top analyst upgrades and downgrades covered by 24/7 Wall St. on Thursday, September 4, 2014.
Companies Betting on the Next 10 Blockbuster Drugs
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
Credit Suisse Says Grit Your Teeth and Buy Biotech
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at…
UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their recent report that the…